Case number 1:22-cv-01124
Neurocrine Biosciences, Inc. v. Sandoz Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Oct 6, 2023 | 18 | Official Transcript of Motion to Amend held on 8/3/23 before Judge Laura Hatcher. Court Reporter Deanna Warner, Email: deanna_warner@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 10/27/2023. Redacted Transcript Deadline set for 11/6/2023. Release of Transcript Restriction set for 1/4/2024. (Warner, Deanna) (Entered: 10/06/2023) (41) |
| Oct 5, 2023 | 15 | STIPULATION of Dismissal Without Prejudice (as to Sandoz Inc., Crystal Pharmaceutical (Suzhou) Co., Ltd., and Crystal Pharmatech Co., Ltd.) by Neurocrine Biosciences, Inc. (Balick, Steven) Modified on 10/5/2023 (dlw). (Entered: 10/05/2023) (2) |
| Oct 5, 2023 | 16 | SO ORDERED re (23 in 1:21-cv-01067-MN, 22 in 1:21-cv-01464-MN, 15 in 1:22-cv-01124-MN, 253 in 1:21-cv-01042-MN) Stipulation of Dismissal (as to Sandoz Inc., Crystal Pharmaceutical (Suzhou) Co., Ltd., and Crystal PharmatechCo., Ltd.) Party Crystal Pharmaceutical (Suzhou) Co., Ltd., Crystal Pharmatech Co., Ltd., and Sandoz Inc. terminated. Attorney Stephanie T. Coelho; Elizabeth M. Crompton; Scott A. Cunning, II; Ronald P. Golden, III; Zoe A. Goldstein; C. Kyle Musgrove; John C. Phillips, Jr; David A. Bilson and Stephen B. Brauerman terminated as to these Defendants. Signed by Judge Maryellen Noreika on 10/5/2023. (dlw) (Entered: 10/05/2023) (2) |
| Oct 5, 2023 | 17 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s). (Attachments: # 1 Stipulation of Dismissal)(mdb) (Entered: 10/05/2023) (0) |
| Aug 3, 2023 | 14 | ORAL ORDER granting Motion for Leave to Amend (D.I. 12). Defendants shall promptly file the Amended Answer, Affirmative Defenses, and Counterclaims attached to D.I. 12 as Exhibit A. Ordered by Judge Laura D. Hatcher on 8/3/23. (kjk) (Entered: 08/03/2023) (0) |
| Jul 27, 2023 | 13 | [SEALED] Letter to The Honorable Laura D. Hatcher from Andrew C. Mayo regarding response to Defendants' July 20, 2023 letter - re 12 Letter,,. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D)(Mayo, Andrew) (Entered: 07/27/2023) (0) |
| Jul 20, 2023 | 12 | [SEALED] Letter to Honorable Laura D. Hatcher from Stephen B. Brauerman regarding Motion for Leave. (Attachments: # 1 Exhibit A to Letter, # 2 Exhibit B to Letter, # 3 Exhibit C to Letter, # 4 Exhibit D to Letter, # 5 Exhibit E to Letter, # 6 Exhibit Amended Answer, # 7 Exhibit A to Ans., # 8 Exhibit B to Ans., # 9 Exhibit C to Ans., # 10 Exhibit D to Ans., # 11 Exhibit E to Ans., # 12 Exhibit F to Ans., # 13 Exhibit G. to Ans., # 14 Exhibit H to Ans., # 15 Exhibit I to Ans., # 16 Exhibit J to Ans., # 17 Exhibit K to Ans., # 18 Exhibit L to Ans., # 19 Exhibit M to Ans., # 20 Exhibit N to Ans., # 21 Exhibit O to Ans., # 22 Exhibit P to Ans., # 23 Certificate of Service)(Golden, Ronald) (Entered: 07/20/2023) (0) |
| Nov 22, 2022 | 11 | ANSWER to 1 Complaint, , COUNTERCLAIM against Neurocrine Biosciences, Inc. by Crystal Pharmatech Co., Ltd., Sandoz Inc., Crystal Pharmaceutical (Suzhou) Co., Ltd..(Golden, Ronald) (Entered: 11/22/2022) (25) |
| Nov 10, 2022 | 10 | STIPULATION Seeking to Extend the Deadline by Which the Parties in the Non-Consolidated Cases Must Inform the Court Whether they Agree to be Consolidated With, and Adopt the Schedule of the Lead Case, by Neurocrine Biosciences, Inc.. (Balick, Steven) (Entered: 11/10/2022) (5) |
| Oct 19, 2022 | 9 | ORAL ORDER RESETTING Teleconference - IT IS HEREBY ORDERED that the 10/24/2022 teleconference is RESET for 11/3/2022 at 02:00 PM before Judge Maryellen Noreika. Counsel shall provide a teleconference dial-in number and code for the teleconference by emailing this Court's judicial administrator. ORDERED by Judge Maryellen Noreika on 10/19/2022. (dlw) (Entered: 10/19/2022) (0) |
| Oct 13, 2022 | 8 | SO ORDERED re (7 in 1:22-cv-01124-MN) (62 in 1:21-cv-01042-MN) Stipulation as to Joinder and Dismissal of Certain Parties and Order. Signed by Judge Maryellen Noreika on 10/13/2022. (dlw) (Entered: 10/13/2022) (7) |
| Oct 12, 2022 | 7 | STIPULATION as to Joinder and Dismissal of Certain Parties and [Proposed] Order by Crystal Pharmaceutical (Suzhou) Co., Ltd., Crystal Pharmatech Co., Ltd., Sandoz AG, Sandoz Inc., Sandoz International GmbH. (dlw) (Entered: 10/13/2022) (7) |
| Oct 6, 2022 | 6 | ORAL ORDER Setting Teleconference: IT IS HEREBY ORDERED that a Telephone Conference is set for 10/24/2022 at 02:00 PM before Judge Maryellen Noreika. Counsel shall provide a teleconference dial-in number and code for the teleconference by emailing this Court's judicial administrator. ORDERED by Judge Maryellen Noreika on 10/6/2022. (dlw) (Entered: 10/06/2022) (0) |
| Aug 26, 2022 | 1 | Complaint* (1) |
| Aug 26, 2022 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (lam) (Entered: 08/29/2022) (3) |
| Aug 26, 2022 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 7/15/2022. Date of Expiration of Patent: See Attachment.Thirty Month Stay Deadline: 10/11/2024. (lam) (Entered: 08/29/2022) (2) |
| Aug 26, 2022 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,039,627 ;8,357,697 ;11,311,532. (lam) (Entered: 08/29/2022) (1) |
| Aug 26, 2022 | 5 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Neurocrine Biosciences, Inc.. (lam) (Entered: 08/29/2022) (1) |
